Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Liabilities and Shareholders Equity (2019 - 2026)

Enliven Therapeutics has reported Liabilities and Shareholders Equity over the past 8 years, most recently at $464.9 million for Q1 2026.

  • Quarterly results put Liabilities and Shareholders Equity at $464.9 million for Q1 2026, up 53.63% from a year ago — trailing twelve months through Mar 2026 was $1.9 billion (up 53.54% YoY), and the annual figure for FY2025 was $476.2 million, up 46.17%.
  • Liabilities and Shareholders Equity reached $464.9 million in Q1 2026 per ELVN's latest filing, down from $476.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $503.9 million in Q2 2025 and bottomed at $59.1 million in Q3 2022.
  • Median Liabilities and Shareholders Equity over the past 5 years was $302.9 million (2023), compared with a mean of $292.1 million.
  • The largest annual shift saw Liabilities and Shareholders Equity tumbled 44.78% in 2022 before it soared 363.66% in 2023.
  • Over 5 years, Liabilities and Shareholders Equity stood at $83.3 million in 2022, then soared by 226.38% to $271.9 million in 2023, then increased by 19.82% to $325.8 million in 2024, then skyrocketed by 46.17% to $476.2 million in 2025, then fell by 2.38% to $464.9 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for ELVN at $464.9 million in Q1 2026, $476.2 million in Q4 2025, and $490.9 million in Q3 2025.